InvestorsHub Logo
Followers 86
Posts 12714
Boards Moderated 0
Alias Born 10/12/2010

Re: Protector post# 287123

Wednesday, 02/07/2018 5:52:49 PM

Wednesday, February 07, 2018 5:52:49 PM

Post# of 345969
CP, it looks like LabCorp (and which bought Covance) could use PS Targeting patents and related Biomarkers to shore up their future collaborations with BMS.

Hopefully CEO Roger Lias still has his contacts at Covance handy....because Covance would likely see the value in PS Targeting IP and Exosomes related Biomarkers....more than just residual values.

FRI SEP 2, 2016 / 7:28 AM EDT
Judge invalidates LabCorp unit's genetic testing patents

A federal judge has invalidated four patents on genetic tests to be used in cancer treatment belonging to a Laboratory Corporation of America Holdings unit, finding they claimed unpatentable laws of nature.

The ruling, handed down Wednesday by U.S. District Judge Allison Burroughs in Boston, is a victory for German diagnostics company Qiagen NV, which had challenged the patents. It follows an order from Burroughs in the same case last September invalidating a similar patent on the same grounds.

To read the full story on Westlaw Practitioner Insights, click here: bit.ly/2bVuGx8


https://www.google.com/amp/mobile.reuters.com/article/amp/idUSL1N1BE0D4

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CDMO News